High/moderate-efficacy DMTs cut sNfL ~40% and are associated with bigger gains in disability & relapse reduction; compared to first-line therapies.
sNfL decline tracks EDSS/motor improvement (age-independent), but not psychiatric outcomes →
biomarker potential.
Paper below ⬇️⬇️
Disease-modifying therapies (DMTs) are widely used to manage multiple sclerosis (MS), but their effects on serum neurofilament light chain (sNfL), par…
